Suppr超能文献

绝经后激素治疗联合或不联合补充叶酸对血清同型半胱氨酸水平的影响。

The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level.

作者信息

Toprak A, Erenus M, Ilhan A H, Haklar G, Fak A S, Oktay A

机构信息

Department of Cardiology, Marmara University School of Medicine, Istanbul, Turkey.

出版信息

Climacteric. 2005 Sep;8(3):279-86. doi: 10.1080/13697130500191040.

Abstract

OBJECTIVE

To evaluate the effects of postmenopausal hormone therapy (HT) with or without the addition of folic acid (FA) on serum homocysteine levels in a randomized, placebo-controlled design. Additionally, a non-randomized control group with no treatment was included.

METHODS

Forty non-hysterectomized healthy postmenopausal women were randomly allocated to receive either oral continuous combined HT (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily) and oral folic acid (5 mg/day, n = 20) or HT and placebo (n = 20) for 3 months. A control group (n = 15) did not receive any study medication and was followed in the same manner. The fasting total serum homocysteine level was measured by fluorescence polarization immunoassay with a sensitivity of < 0.5 micromol/l. Serum levels of folate, estrogen and lipid profile were also followed.

RESULTS

The mean age of the postmenopausal women was 52 +/- 6 years. Baseline homocysteine level was the highest in the HT + FA group (9.96 +/- 2.82 micromol/l), compared to HT + placebo (9.64 +/- 1.89 micromol/l) and control groups (9.01 +/- 1.83 micromol/l) (ANCOVA, p = 0.022). Low baseline folate and vitamin B12 levels contributed significantly to the high level of baseline homocysteine in the HT + FA group. The addition of FA to HT led to a significant decrease in the serum homocysteine level from the baseline level of 9.96 +/- 2.82 micromol/l to the final level of 8.92 +/- 2.53 micromol/l (p = 0.023). On the other hand, HT alone (HT + placebo group) significantly increased the serum homocysteine level from 9.64 +/- 1.89 micromol/l to 10.22 +/- 1.77 micromol/l without a decline in serum folate level (p = 0.045). The serum homocysteine level in the control group did not change significantly (from 9.01 +/- 1.83 micromol/l to 9.58 +/- 2.05 micromol/l, p = 0.29).

CONCLUSIONS

Three months of oral continuous combined HT increased the fasting total serum homocysteine level without affecting the serum folate level. Lowering the homocysteine level in postmenopausal woman on HT is achievable by folic acid supplementation.

摘要

目的

采用随机、安慰剂对照设计,评估绝经后激素治疗(HT)加或不加叶酸(FA)对血清同型半胱氨酸水平的影响。此外,纳入一个未接受治疗的非随机对照组。

方法

40名未行子宫切除术的健康绝经后女性被随机分配,分别接受口服连续联合HT(每日0.625mg结合马雌激素与2.5mg醋酸甲羟孕酮)及口服叶酸(5mg/天,n = 20),或HT及安慰剂(n = 20),为期3个月。一个对照组(n = 15)未接受任何研究药物,并以相同方式随访。采用灵敏度<0.5微摩尔/升的荧光偏振免疫分析法测量空腹血清总同型半胱氨酸水平。还对血清叶酸、雌激素水平及血脂情况进行随访。

结果

绝经后女性的平均年龄为52±6岁。HT + FA组的基线同型半胱氨酸水平最高(9.96±2.82微摩尔/升),相比之下,HT + 安慰剂组为(9.64±1.89微摩尔/升),对照组为(9.01±1.83微摩尔/升)(协方差分析,p = 0.022)。低基线叶酸和维生素B12水平是导致HT + FA组基线同型半胱氨酸水平高的重要因素。HT加用FA导致血清同型半胱氨酸水平从基线水平9.96±2.82微摩尔/升显著降至最终水平8.92±2.53微摩尔/升(p = 0.023)。另一方面,单纯HT(HT + 安慰剂组)使血清同型半胱氨酸水平从9.64±1.89微摩尔/升显著升至10.22±1.77微摩尔/升,而血清叶酸水平未下降(p = 0.045)。对照组的血清同型半胱氨酸水平无显著变化(从9.01±1.83微摩尔/升至9.58±2.05微摩尔/升,p = 0.29)。

结论

三个月的口服连续联合HT可提高空腹血清总同型半胱氨酸水平,且不影响血清叶酸水平。补充叶酸可降低接受HT的绝经后女性的同型半胱氨酸水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验